Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Encore? FDA Could Come Close To Record 2012 NME Count This Year

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

With 19 novel agents approved so far in 2013 and a full slate of candidates under review, the recovery in novel agent approvals after the doldrums of the 2000s is likely to continue even if the agency falls short of last year’s 45 approvals. Watch for action on the first “breakthrough” therapies submitted and advances in hepatitis C treatment.

Advertisement

Related Content

Oncologists Reject Reps’ Advances, While Pharma Keeps Paying The Tab
FDA Needs More Time To Review Sugammadex Inspection Report, Cancels Advisory Committee
Alzheimer’s Community Prepares To Challenge CMS Amyvid Proposal
Federal Task Force Recommends One-Time HCV Screening For All Baby Boomers
PhRMA, BIO’s PDUFA V Application Tracker Could Inform “Course Corrections”
Eliquis Approval Delayed By Fraud, Dispensing Errors In Pivotal Trial
Dynavax Will Not Pursue Narrow Indication For Heplisav After Meeting With FDA
What’s Breakthrough Status Worth? Analysts Ask, But Companies Don’t Have Answers
Are The 90s Back? Oncologics Drove FDA’s 2012 Novel Approval Count To 15-Year High
Settling In To The “New Normal”: Midway Through 2012, Another Banner Year For Drug Approvals Is Within Reach

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS005464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel